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 ABSTRACT 25 
Background: Maintenance of skeletal muscle in older age is critical to reducing frailty and the risk of 26 
falls and fractures. Nutrition has established importance for muscle health in general, but less research 27 
has looked at associations of dietary intake of specific micronutrients on skeletal muscle mass in older 28 
adults. 29 
Aims: This study aimed to investigate the influence of dietary and circulating magnesium on skeletal 30 
muscle mass in a UK population of 14,340 middle to older-aged men and women participating in the 31 
EPIC-Norfolk cohort study. 32 
Methods: Dietary nutrient intakes were estimated from 7-day food diaries and fat-free mass (FFM) by 33 
bioelectrical impedance analysis. Multivariable regression was used to investigate associations of 34 
FFM-based indices of muscle mass with quintiles of dietary magnesium intake or serum magnesium 35 
concentration groups. All analyses were stratified by sex, and regression models were adjusted for 36 
relevant covariates. 37 
Results: Significant positive trends in FFM measures were evident across magnesium dietary intake 38 
quintiles for both sexes (all p<0.001; n=6350 men; n=7990 women) and both <60 and ≥60 year olds, 39 
with all-age quintile 5 versus quintile 1 maximal differences of 4.6% in men and 6.3% in women; 40 
highly relevant compared to the estimated 1% decline per year after 40 years of age. These 41 
observations were not reflected in serum magnesium analyses, where no consistent trends were found 42 
across the skeletal muscle mass indices tested. 43 
Conclusion: Further investigation will be required to improve our understanding of the relationship 44 
between serum magnesium concentration and skeletal muscle mass. However, this study has 45 
demonstrated strong associations between dietary magnesium intake and indices of skeletal muscle 46 
mass in a UK population of middle to older-aged adults, highlighting the likely importance of dietary 47 
magnesium for optimal muscle health in this population.  48 
 49 
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 INTRODUCTION 51 
Sarcopenia is a syndrome characterised by a progressive and generalised loss of skeletal muscle mass 52 
and function with age (1). Significant reduction in skeletal muscle mass and strength impairs static 53 
and dynamic balance, which may increase risk of falls and thus the risk of resultant fractures (2). 54 
Indirectly, the maintenance of skeletal muscle is important in protecting against osteoporosis since the 55 
mechanical force of muscle contractions stimulates bone modelling and remodelling, which increases 56 
bone strength and mass (3). Previous research has also shown skeletal muscle mass to be positively 57 
correlated with both bone mineral content and density (2). Sarcopenia can therefore have significant 58 
implications for affected individuals, placing them at risk of adverse outcomes including physical 59 
frailty and falls, and resulting in an increased need for health and social care services (4). Muscle 60 
tissue also has a metabolic role in the body and thus loss of muscle mass may result in other 61 
detrimental outcomes, including change to metabolic rate, insulin resistance, and increased risk of 62 
hypertension (5). 63 
 64 
Sarcopenia is a complex condition, with many contributory factors including hormonal changes, 65 
decreased protein synthesis, low-grade inflammation, oxidative stress, mitochondrial dysfunction, and 66 
neuromuscular ageing. Nevertheless, interventions targeting modifiable lifestyle behaviours, such as 67 
physical activity or diet, provide a potential strategy to reduce severity (4). It is recognised that 68 
appropriate nutrition is critical for normal muscle metabolism, but influences of specific dietary 69 
nutrients on sarcopenia are less well defined. Dietary protein has received most attention in the past 70 
(6), but more recently the importance of other dietary components, including vitamin D (7) and 71 
antioxidant micronutrients vitamins C (8) and E (9,10), has been suggested. Likewise, the mineral 72 
magnesium has drawn some attention. Older individuals may be particularly susceptible to developing 73 
low magnesium status due to physiological decline in function of the gastrointestinal and renal 74 
systems causing a reduction in absorption of dietary magnesium and an increase in urinary excretion 75 
(11). Second only to bone, skeletal muscle acts as a major store of magnesium where it is important 76 
 for energy metabolism, transmembrane transport, and muscle contraction and relaxation (12). 77 
Magnesium supplementation has been shown to increase the muscle strength young adults gained 78 
through exercise (13) and improve physical performance in older individuals (14). Epidemiological 79 
studies have shown higher dietary magnesium intakes associated with greater skeletal muscle mass 80 
and function (15) (16,17), and a significant positive association of serum magnesium concentration 81 
with muscle performance in older adults (18). However, a comprehensive population cohort analysis 82 
of dietary and circulating magnesium associations with skeletal muscle measures in both men and 83 
women is currently lacking. This study therefore aims to address this by exploring the potential 84 
associations of dietary magnesium intake and serum magnesium concentration with bio-impedance 85 
estimated fat free mass (as a measure of skeletal muscle mass), in a mixed-sex UK population of 86 
middle to older-aged individuals. 87 
 88 
MATERIALS AND METHODS 89 
Data analysed in this cross-sectional cohort study were from the Norfolk component of the European 90 
Prospective Investigation into Cancer and Nutrition (EPIC). Written informed consent was provided 91 
by participants according to the Declaration of Helsinki, and all procedures were approved by The 92 
Norfolk District Health Authority Ethics Committee. Full details of recruitment to this cohort and the 93 
procedures involved have been described previously (19). In summary, 25,639 men and women aged 94 
40-79 years old living in the general community in Norfolk, UK, were recruited to the study and 95 
participated in a baseline health-check between 1993 and 1997. Of these, 15,028 participants aged 42-96 
82 years had further data recorded at a second health-check between 1997 and 2000, when 97 
bioelectrical impedance analysis (BIA) was undertaken. 98 
 99 
At both health checks, height and weight were measured according to standard protocols (19). Height 100 
was recorded to the nearest millimetre using a free-standing stadiometer and weight to the nearest 0.1 101 
kilograms using calibrated digital scales with the participant wearing light clothing and no shoes. BMI 102 
 was calculated from these measurements (kg/m
2
). BIA was carried out using a previously validated 103 
(20,21) standard technique (Bodystat, Isle of Man, UK). The Tanita TBF-531 BIA analyser calculated 104 
body density (BD) from total weight (Wt) in kg, height (Ht) in cm, and impedance (Z) in ohms, using 105 
the following standard regression formulae for adults: BD in men = 1.100455 – 0.109766 × Wt × Z ÷ 106 
Ht
2
 + 0.000174 × Z; BD in women = 1.090343 – 0.108941 × Wt × Z ÷ Ht
2
 + 0.00013 × Z. From this, 107 
fat free mass (FFM) in kg was calculated: FFM = Wt – ((4.57 ÷ BD – 4.142) × Wt). This estimates the 108 
total mass of non-fat compartments of the body, i.e. metabolic tissue, intra- and extra-cellular water, 109 
and bone tissue. As a further index for assessment, percentage FFM (FFM%) was calculated as FFM 110 
divided by total weight multiplied by 100, and in order to scale for differences in skeletal muscle mass 111 
with increasing body weight or stature, FFM standardised by BMI (FFMBMI) was calculated as FFM 112 
divided by BMI (22). 113 
 114 
Health and lifestyle questionnaires, as previously described (19), were completed by all participants to 115 
gather data including age, physical activity, social class, smoking status, menopausal status and HRT 116 
use, and corticosteroid use. Each participant’s physical activity status was categorised, according to a 117 
heart-rate data validated method (19,23), as inactive, moderately inactive, moderately active, or active. 118 
Dietary intakes were assessed using 7 day food diaries completed by each participant detailing all 119 
food and drink consumed, together with the portion sizes (24). DINER (Data Into Nutrients for 120 
Epidemiological Research) software was used to enter the dietary information provided by the diaries 121 
(25), which was then checked and processed by nutritionists to obtain nutrient data, using DINERMO 122 
(26). Serum magnesium concentration was determined using blood sampled by peripheral 123 
venepuncture during the baseline health check. Samples were prepared, using a technique optimised 124 
for use in EPIC, and stored in liquid nitrogen at -196ºC until analysed by Quotient Bioresearch, 125 
Fordham, UK, using an Olympus AU640 Chemistry Immuno Analyser to perform a xylidyl blue 126 
based colorimetric assay (Beckman Coulter, USA). Measurements below 0.2 mmol/L or above 3.3 127 
mmol/L were considered invalid and excluded from analyses. 128 
  129 
The High Performance Computing Cluster supported by the Research and Specialist Computing 130 
Support service at the University of East Anglia was used for statistical data analysis with STATA 131 
software (v.13; Stata Corp., Texas). All analyses were stratified by sex since significant differences in 132 
body composition and skeletal muscle mass exist between men and women. Any p values <0.05 were 133 
considered to be statistically significant in individual analyses. Multivariable regression with 134 
ANCOVA was used to investigate differences in skeletal muscle measures across sex-specific 135 
quintiles of dietary magnesium intake. An adjusted model was tested, correcting for the potential 136 
effects of physiological (age, menopausal status, HRT status, corticosteroid use, statin use), lifestyle 137 
(smoking status, physical activity, social class) and dietary factors (total energy intake, and the 138 
percentage of total energy from protein); also included was the energy intake to estimated energy 139 
requirement ratio (EI:EER) as a percentage, to help correct for dietary misreporting (27). Likewise, 140 
differences in skeletal muscle measures across sex-specific groups of serum magnesium concentration 141 
were investigated using the same covariates, but excluding dietary factors in the adjusted model. 142 
Serum magnesium concentration in healthy individuals is kept under tight homeostatic control; 143 
published guidance suggests 0.7-1.0 mmol/L should be used as a reference range for healthy 144 
individuals (28). Serum magnesium concentration groups were therefore categorised as <0.7 mmol/L 145 
(group 1), 0.7-0.8 mmol/L (group 2), 0.8-0.9 mmol/L (group 3), 0.9-1.0 mmol/L (group 4), and >1.0 146 
mmol/L (group 5). Group 2 has been used as the reference category for inter-group analyses. 147 
Participants were excluded from analyses if they had missing or extreme (<300 or >1000 ohms (29)) 148 
BIA impedance values (n=228 and n=22), FFM < 25kg (n=13), BMI ≥ 36 kg/m
2
 (n=337), or had 149 
missing values for any covariates included in the multivariable model (n=88 for diet analyses, and 150 
n=48 for serum analyses). Analyses were repeated after stratifying for age (<60 and ≥60 years). 151 
Correlation between dietary and serum continuous scale magnesium variables was assessed by 152 
Pearson correlation coefficient. 153 
 154 
 RESULTS 155 
Selected characteristics of participants are summarised in Table 1 stratified by sex. All variables were 156 
significantly different in men and women except for corticosteroid and statin use. The UK Reference 157 
Nutrient Intake (RNI) for magnesium is 300 mg per day for men over the age of 18 years and 270 mg 158 
per day for women, while the Estimated Average Requirements (EARs) for men and women are 250 159 
mg and 200 mg (30). In this cohort, mean dietary magnesium intakes were 332 ± 90 mg for men and 160 
275 ± 73 mg for women. The largest contribution of magnesium in the diet of both men and women in 161 
this cohort came from cereals and cereal foods (33.7% of total dietary magnesium in men; 32.4% in 162 
women). Fruits and vegetables accounted for a further 11.5% in men and 15.0% in women, while hot 163 
beverages provided 10.1% in men and 11.4% in women. Further detail of the contribution of foods to 164 
magnesium intake is provided in Supplemental Figure 1. Prevalence of inadequate intakes estimated 165 
using the EAR cut-point method (31) was 14.3%, with a greater number of men with inadequate 166 
intakes than women (16.1% vs. 12.9%; p<0.001; n=14340). No correlation was evident between 167 
magnesium dietary intake and serum concentration (Pearson’s r=0.007, p=0.646, n=4611 men; r=-168 
0.030, p=0.020, n=5972 women). 169 
 170 
In dietary model analyses, there were significant positive trends across magnesium intake quintiles in 171 
adjusted FFM, FFM%, and FFMBMI for both men and women (all p<0.001; n=6350 men; n=7990 172 
women) (see Supplemental Table 1). These trends were evident in both <60 (n=2366 men; n=3535 173 
women) and ≥60 year olds (n=3984 men; n=4455 women) (see Figure 1). The largest all-age inter-174 
quintile differences were apparent in women where adjusted FFM for those in quintile 5 was 2.9% 175 
greater than in quintile 1, FFM% was 4.2% greater, and FFMBMI was 6.3% greater (all p<0.001; 176 
n=3196); quintile 5 vs. 1 differences in men were 2.0% for FFM, 2.4% for FFM%, and 4.6% for 177 
FFMBMI (all p<0.001; n=2540). For women under 60 years of age, adjusted FFM in quintile 5 was 178 
3.4% greater than in quintile 1, FFM% was 4.6% greater, and FFMBMI was 7.2% greater (all p<0.001; 179 
n=1394); in men the differences were 2.2% for FFM, 2.2% for FFM%, and 4.8% for FFMBMI (all 180 
 p<0.001; n=940). For women 60 years or over, adjusted FFM in quintile 5 was 2.8% greater than in 181 
quintile 1, FFM% was 4.6% greater, and FFMBMI was 6.8% greater (all p<0.001; n=1802); in men the 182 
differences were 1.8% for FFM, 2.8% for FFM%, and 5.0% for FFMBMI (all p<0.001; n=1600). 183 
 184 
In all-age serum model analyses (see Supplemental Table 2) no linear trends were apparent between 185 
magnesium serum concentration groups and FFM, FFM%, or FFMBMI; likewise, no significant 186 
differences were identified between muscle mass measures in the low normal concentration group 187 
(group 2) vs. other groups. However, stratifying the serum data by age highlighted some significant 188 
differences (see Figure 2). In individuals ≥60 years old, FFM was significantly lower in magnesium 189 
concentration group 4 vs. group 2 in both men (p=0.031; n=1131) and women (p=0.020; n=1311), and 190 
group 5 vs. group 2 in women only (p=0.029; n=928). 191 
 192 
DISCUSSION 193 
This study, using data from a large population cohort, has shown that associations between dietary 194 
magnesium and indices of skeletal muscle mass exist in both men and women. Significant positive 195 
trends in FFM, FFM% and FFMBMI were evident across increasing quintiles of dietary magnesium 196 
intake for both sexes, which remained after adjustment for important biological, lifestyle and other 197 
dietary covariates. These results corroborate previous smaller-scale studies including the positive 198 
relationship between magnesium intake and dual-energy X-ray absorptiometry-assessed appendicular 199 
lean mass in individuals aged 50 to 79 years in the Tasmanian Older Adult Cohort Study (15), the 200 
greater FFM seen with higher intakes of dietary magnesium in a UK study of women aged 34 to 83 201 
years from the TwinsUK cohort (16), and the more recent large-scale cross-sectional analysis of 202 
FFM% and FFMBMI using UK Biobank data (17). Associations between serum magnesium 203 
concentration groups and skeletal muscle mass indices are less clear, although this is unsurprising 204 
considering the tight homeostatic control of circulating magnesium and the fact that less than 1% of 205 
total body magnesium is present in the blood (32). This homeostatic control makes it less likely that a 206 
 serum magnesium concentration outside the normal range represents an extreme dietary intake of 207 
magnesium, and more likely that it is the result of a pathological problem (e.g. abnormal renal 208 
wasting) or diuretic medication (32). Indeed, our results showed correlation of magnesium serum 209 
concentration with dietary intake in the EPIC-Norfolk cohort was negligible. Previous studies have 210 
demonstrated that despite presenting with normal serum magnesium concentration, some individuals 211 
may be severely magnesium deficient, with low concentrations in bone and muscle due to long-term 212 
compensatory release of magnesium to maintain serum concentration when dietary intake has been 213 
low for a long period of time (33). This may partly explain the inconsistent associations between 214 
serum magnesium concentrations and skeletal muscle mass indices apparent in this study.  215 
 216 
It is important to appreciate the magnitude of the differences seen with the dietary analyses. Indeed, 217 
considering that the effect of age on skeletal muscle mass is already well-established (34), and 218 
confirmed in this dataset where FFMBMI was 5.4% lower in those ≥60 years versus those <60 years 219 
(data not shown), the differences seen according to magnesium intake are highly relevant. For 220 
example, the difference in adjusted FFMBMI between magnesium quintile 5 and quintile 1 for women 221 
was 6.3%. Furthermore, the difference in median daily dietary intake between quintiles 1 and 5 for 222 
women was 173 mg, a difference which should be achievable as part of a normal diet (for example, by 223 
½ cup boiled spinach, ¼ cup roasted peanuts, and a medium-sized banana (35)). However, since a 224 
typical Western diet containing a high proportion of processed foods and limited whole grains and 225 
green vegetables is often deficient in magnesium (36), more needs to be done to promote an adequate 226 
diet and avoid adverse musculoskeletal consequences. 227 
 228 
Although sarcopenia is a particular issue in individuals aged 60 years old or older, loss of skeletal 229 
muscle mass has been documented to progress from the age of 30 years onwards (4). Age 230 
stratification of our dietary magnesium analyses demonstrated largely similar effects for those less 231 
than 60 years of age, and those 60 years or older, albeit with lower values for muscle mass indices in 232 
 the older age group. This highlights the potential benefits of dietary magnesium for musculoskeletal 233 
health in all ages of this cohort, and raises the possibility that optimal dietary magnesium intake could 234 
help preserve skeletal muscle before sarcopenia becomes problematic later in life. 235 
 236 
While previous research has demonstrated magnesium status to be strongly correlated with muscle 237 
performance in both young and old individuals (13,14), the mechanisms by which magnesium may 238 
influence muscle are not yet fully understood. Magnesium is critical for basic mitochondrial function: 239 
cell-culture and animal studies have demonstrated that magnesium depletion can cause structural 240 
damage to muscle cells due to oxidative stress and disrupted calcium homeostasis (37). In addition, 241 
magnesium also has a postulated role in protecting against the chronic low-grade inflammation 242 
associated with ageing and a known risk factor for sarcopenia (4). Indeed, circulating concentrations 243 
of inflammatory cytokines, including C-reactive protein (CRP), IL-6, and TNF-α, have been 244 
negatively associated with skeletal muscle measures of both mass and function in a number of studies 245 
(16,38-40), and systematic review evidence indicates that dietary magnesium intake is inversely 246 
associated with serum CRP concentration (41). 247 
 248 
It is interesting to consider how results for the alternative skeletal muscle indices translate into clinical 249 
importance for sarcopenia. FFMBMI may provide a more useful measure than unstandardised FFM or 250 
FFM% to assess change in skeletal muscle mass while correcting for differences attributable to body 251 
size. This index has recently been used to define cutpoints in the Foundation for the National Institutes 252 
of Health Biomarkers Consortium Sarcopenia Project (42), and as it is used in more studies of 253 
different populations we will gain a greater understanding of how it describes body composition in 254 
both normal and sarcopenic individuals. 255 
 256 
This is the first study to have investigated associations between both dietary intake and circulating 257 
magnesium, and measures of skeletal muscle in a mixed-sex UK cohort of older adults. However, we 258 
 recognise there are a number of limitations. These include the observational and cross-sectional study 259 
design which precludes us from attributing causal links between magnesium dietary intake or serum 260 
concentration and skeletal muscle measures, and reliance on self-reported measures for diet and 261 
physical activity data. Nevertheless, the quantitative 7-day food diaries developed for use in EPIC 262 
have been validated previously and are expected to provide more precise dietary intake figures 263 
compared to alternative FFQ or 24-hour recall methods (26). Magnesium dietary data analysed here 264 
were derived from food intake only, and therefore may underestimate total nutrient intakes. However, 265 
the supplements consumed by this cohort provide a relatively small contribution to total magnesium 266 
intake and thus are likely to have a negligible effect on our results (43). We assessed magnesium 267 
status using serum magnesium concentrations which may not be the most reliable marker of Mg status 268 
as discussed earlier. However, the preferred alternative of timed 24 hour urine collection which 269 
linearly reflects dietary intake may be even less reliable for older individuals due to problems with 270 
urine collection and complications of diuretic use (11). Magnetic resonance measurement of ionised 271 
magnesium within skeletal muscle could provide useful data (44), but this method was not practical 272 
for our large population sample, and thus serum magnesium measurement remains a useful indicator 273 
of magnesium status for this type of study (45). Indices of skeletal muscle mass were calculated from 274 
weight, height, and bioelectrical-impedance measurements, rather than the potentially more accurate 275 
and precise methods of dual-energy X-ray absorptiometry, computer tomography, or magnetic 276 
resonance imaging (46). However, bio-electrical impedance assessment has the advantage of avoiding 277 
accessibility issues, costs, and radiation, associated with other methods. Consequences of loss of 278 
skeletal muscle mass may extend beyond a reduction in strength and function due to the metabolic 279 
role of muscle, and may include changes to metabolic rate, insulin resistance, and increased risk of 280 
hypertension (5). While in this study it has not been possible to analyse functional muscle measures in 281 
relation to magnesium we believe it is important to have considered the fundamental body 282 
composition information provided by BIA data. 283 
 284 
 Conclusions 285 
This study has highlighted strong positive associations between dietary magnesium intake and indices 286 
of skeletal muscle mass in both men and women of the EPIC-Norfolk cohort, with the scale of effects 287 
highly relevant in comparison to age-related losses. The results for circulating magnesium are less 288 
patent, potentially due to the tight homeostatic control of blood magnesium concentrations. These 289 
findings, which being observational in nature require confirmation by clinical trial, support a 290 
hypothesis that dietary magnesium is beneficial to skeletal muscle health in older individuals. 291 
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 TABLES AND FIGURES 423 
 424 
Table 1 – Selected characteristics of the EPIC-Norfolk cohort population stratified by sex for the diet 425 
analysis group (n=14,340) and the serum analysis group (n=10,611). 426 
 427 
Selected Characteristics Diet analysis group
 
 Serum analysis group
 
 
 Men Women  Men Women  
 n=6350 n=7990 P
1
 n=4628 n=5983 P 
Age (years) 62.9 ± 9.0
2
 61.5 ± 9.0 <0.001 62.9 ± 8.7
2
 61.6 ± 8.9 <0.001 
BMI (kg/m
2
) 26.7 ± 3.0 26.1 ± 3.7 <0.001 26.7 ± 3.0 26.0 ± 3.7 <0.001 
Magnesium intake (mg/day) 332 ± 90 275 ± 73 <0.001 -- --  
Total energy intake (kcal/day) 2286 ± 500 1735 ± 378 <0.001 -- --  
Protein % of energy 14.8 ± 2.4 15.5 ± 2.8 <0.001 -- --  
Serum [Mg] (mmol/L) -- --  0.82 ± 0.11 0.80 ± 0.12 <0.001 
FFM (kg) 61.6 ± 5.9 40.6 ± 4.5 <0.001 61.7 ± 5.9 40.6 ± 4.5 <0.001 
FFM% 76.7 ± 5.8 60.9 ± 8.3 <0.001 76.8 ± 5.8 61.1 ± 8.1 <0.001 
FFMBMI 2.33 ± 0.26 1.58 ± 0.26 <0.001 2.33 ± 0.26 1.59 ± 0.26 <0.001 
EI/EER% 91.1 ± 20.7 93.7 ± 21.8 <0.001 -- --  
Smoking   <0.001   <0.001 
     Current 542 (8.5) 696 (8.7)  375 (8.1) 489 (8.2)  
     Former 3524 (55.5) 2551 (31.9)  2552 (55.1) 1909 (31.9)  
     Never 2284 (36.0) 4743 (59.4)  1701 (36.8) 3585 (59.9)  
Physical activity   <0.001   <0.001 
     Inactive 1736 (27.3) 2070 (25.9)  1236 (26.7) 1537 (25.7)  
     Moderately inactive 1595 (25.1) 2600 (32.5)  1164 (25.2) 1927 (32.2)  
     Moderately active 1590 (25.0) 1933 (24.2)  1160 (25.1) 1445 (24.2)  
     Active 1429 (22.5) 1387 (17.4)  1068 (23.1) 1074 (18.0)  
Corticosteroid use   0.391   0.391 
     Never (<3 months) 6086 (95.8) 7583 (94.9)  4444 (96.0) 5698 (95.2)  
     Current or former (>3 months) 264 (4.2) 407 (5.1)  184 (4.0) 285 (4.8)  
Statin use   0.391   0.391 
     No 6003 (94.5) 7700 (96.4)  4389 (94.8) 5769 (96.4)  
     Yes 347 (5.5) 290 (3.6)  239 (5.2) 214 (3.6)  
Menopausal status       
     Pre-menopausal -- 475 (5.9)  -- 475 (5.9)  
     Peri-menopausal (<1 y) -- 266 (3.3)  -- 266 (3.3)  
     Peri-menopausal (1-5 y) -- 1400 (17.5)  -- 1400 (17.5)  
     Post-menopausal -- 5849 (73.2)  -- 5849 (73.2)  
HRT       
     Current -- 1704 (21.3)  -- 1704 (21.3)  
      Former -- 1432 (17.9)  -- 1432 (17.9)  
     Never -- 4854 (60.8)  -- 4854 (60.8)  
Social Class   <0.001   <0.001 
     Professional 523 (8.2) 547 (6.8)  385 (8.3) 401 (6.7)  
     Managerial 2587 (40.7) 2950 (36.9)  1917 (41.4) 2226 (37.2)  
     Skilled non-manual 797 (12.6) 1554 (19.4)  567 (12.3) 1180 (19.7)  
     Skilled manual 1422 (22.4) 1577 (19.7)  1055 (22.8) 1190 (19.9)  
     Semi-skilled 781 (12.3) 950 (11.9)  537 (11.6) 688 (11.5)  
     Non-skilled 149 (2.3) 267 (3.3)  99 (2.1) 197 (3.3)  
     Un-coded 91 (1.4) 145 (1.8)  68 (1.5) 101 (1.7)  
1
P values are for differences between men and women, according to t-test for continuous or chi-square 428 
for categorical variables. 
2
Values are mean ± SD or frequency (percentage).429 
 Figure 1 – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by 430 
sex, age group, and quintiles of dietary magnesium intake (n=14,340). 431 
 432 
*
 p<0.05; 
**
 p<0.01; 
***
 p<0.001 versus quintile 1, according to ANCOVA. 433 
Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status, 434 
physical activity, social class, total energy intake, percentage of total energy from protein, and 435 
EI:EER. 436 
Values are presented as mean ± SE. 437 
Mg intake (mean ± SD; mg/day) by Mg quintiles (Q). Men ≤60 years: Mean, 350 ± 92; Q1, 226 ± 438 
30; Q2, 283 ± 12; Q3, 323 ± 11; Q4, 368 ± 15; Q5, 470 ± 73. Men >60 years: Mean, 322 ± 87; Q1, 439 
223 ± 31; Q2, 282 ± 12; Q3, 322 ± 11; Q4, 366 ± 16; Q5, 465 ± 71. Women ≤60 years: Mean, 285 ± 440 
75; Q1, 187 ± 27; Q2, 235 ± 10; Q3, 268 ± 10; Q4, 305 ± 12; Q5, 385 ± 62. Women >60 years: Mean, 441 
268 ± 71; Q1, 186 ± 26; Q2, 234 ± 10; Q3, 267 ± 10; Q4, 304 ± 13; Q5, 381 ± 56. 442 
 443 
 444 
Figure 2 – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by 445 
sex, age group, and serum concentration groups (n=10,611). 446 
 447 
*
 p<0.05; 
**
 p<0.01; 
***
 p<0.001 versus group 2, according to ANCOVA. 448 
Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status, 449 
physical activity, and social class. 450 
Values are presented as mean ± SE. 451 
Serum Mg concentration groups: <0.7 mmol/L (group 1), 0.7-0.8 mmol/L (group 2), 0.8-0.9 452 
mmol/L (group 3), 0.9-1.0 mmol/L (group 4), and >1.0 mmol/L (group 5). 453 
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Supplemental Figure 1 – Percentage contribution of different foods to the dietary magnesium intake of EPIC-Norfolk cohort participants, stratified by 
sex (n=25,507). 
 
Rice and pasta 1.8% men, 2.0% women; bread and crackers 17.2% men, 16.3% women; breakfast cereals 9.0% men, 9.0% women; cakes, biscuits, and 
desserts 3.8% men, 3.5% women; cereals (not breakfast) 1.9% men, 1.7 women; milk 7.5% men, 8.0 women; cheese 1.4% men, 1.3% women; dairy 
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Men Women
(not milk or cheese) 2.7% men, 3.7 women; eggs 0.7% men, 0.6% women; potatoes 8.5% men, 7.7% women; vegetables and pulses 6.3% men, 6.9% 
women; fruit 5.3% men, 8.1% women; nuts 1.6% men 1.5% women; fish 3.3% men, 3.4% women; meat 7.7% men, 7.1% women; hot beverages 
10.1% men, 11.4% women; soft drinks 0.2% men, 0.2% women; juice 1.1% men 1.5% women; beer 4.4% men, 0.5% women; alcoholic drinks (not 
beer) 2.0% men, 2.0 women; soups and sauces 1.4% men, 1.5 women; snacks 2.1% men, 2.2% women; miscellaneous 0.2% men, 0.2% women. 
Supplemental Table 1 – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by sex and quintiles of dietary 
magnesium intake (n=14,340). 
 Dietary magnesium intake  
 Total  Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5  
 
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE P trend 
Men n=6350  n=1270  n=1270  n=1270  n=1270  n=1270   
FFM (kg) 61.64 0.04 60.88 0.11 61.52*** 0.10 61.82*** 0.09 61.90*** 0.10 62.10*** 0.11 <0.001 
FFM% 76.72 0.06 75.94 0.14 76.36* 0.13 76.56** 0.12 76.92*** 0.13 77.80*** 0.14 <0.001 
FFMBMI 2.33 0.003 2.27 0.008 2.31*** 0.007 2.32*** 0.007 2.34*** 0.007 2.38*** 0.008 <0.001 
 
             
Women n=7990  n=1598  n=1598  n=1598  n=1598  n=1598   
FFM (kg) 40.61 0.04 40.01 0.11 40.45*** 0.09 40.64*** 0.09 40.78*** 0.10 41.19*** 0.11 <0.001 
FFM% 60.91 0.07 59.90 0.19 60.46* 0.16 60.58** 0.16 61.15*** 0.16 62.45*** 0.18 <0.001 
FFMBMI 1.58 0.003 1.54 0.007 1.57*** 0.006 1.57*** 0.006 1.59*** 0.006 1.64*** 0.007 <0.001 
*
 p<0.05; ** p<0.01; *** p<0.001 versus quintile 1. 
Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status, physical activity, social class, total energy intake, 
percentage of total energy from protein, and EI:EER. 
Mg intake (mean ± SD; mg/day) by Mg quintiles (Q). Men: Mean, 332 ± 90; Q1, 224 ± 31; Q2, 282 ± 12; Q3, 322 ± 11; Q4, 367 ± 16; Q5, 467 ± 
72. Women: Mean, 275 ± 73; Q1, 186 ± 25; Q2, 235 ± 10; Q3, 268 ± 10; Q4, 304 ± 13; Q5, 383 ± 73. 
 
 Supplemental Table 2 – Adjusted skeletal muscle measures for individuals of the EPIC-Norfolk cohort stratified by sex and serum concentration 
groups (n=10,611). 
 Serum magnesium concentration group 
 Total  Group 1 Group 2 Group 3 Group 4 Group 5 
 
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE 
Men n=4628  n=480  n=1128  n=2242  n=710  n=68  
FFM (kg) 61.67 0.09 61.43 0.26 61.64 0.17 61.84 0.12 61.27 0.22 61.52 0.70 
FFM% 76.76 0.08 77.18 0.26 76.83 0.17 76.61 0.12 76.89 0.21 76.17 0.69 
FFMBMI 2.33 0.004 2.33 0.011 2.33 0.007 2.33 0.005 2.32 0.009 2.34 0.030 
 
            
Women n=5983  n=845  n=1694  n=2721  n=661  n=62  
FFM (kg) 40.64 0.06 40.62 0.15 40.77 0.11 40.62 0.09 40.38 0.17 40.32 0.57 
FFM% 61.09 0.10 60.99 0.28 61.04 0.20 61.17 0.15 61.05 0.31 60.42 1.02 
FFMBMI 1.59 0.003 1.58 0.009 1.59 0.006 1.59 0.005 1.59 0.010 1.58 0.032 
Adjusted for: age, menopausal status, HRT status, corticosteroid use, statin use, smoking status, physical activity, and social class. 
Serum Mg concentration groups: <0.7 mmol/L (group 1), 0.7-0.8 mmol/L (group 2), 0.8-0.9 mmol/L (group 3), 0.9-1.0 mmol/L (group 4), and >1.0 
mmol/L (group 5). 
 
